Gyre Therapeutics
GYRE
74 hedge funds and large institutions have $100M invested in Gyre Therapeutics in 2013 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 14 closing their positions.
100% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $1.02M
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
0% more funds holding
Funds holding: 74 → 74 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
25% less capital invested
Capital invested by funds: $135M → $100M (-$34.1M)
Top Buyers
| 1 |
DM
Deerfield Management
New York
|
+$3.09M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.5M |
| 3 |
BC
Broadfin Capital
New York
|
+$1.5M |
| 4 |
Goldman Sachs
New York
|
+$1.1M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$926K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BBA
76
Baker Bros. Advisors
New York
| – | -$11M | -2,626 | Closed |
|
|
HVC
77
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| – | -$1.08M | -257 | Closed |
|
|
JGC
78
J. Goldman & Co
New York
| – | -$929K | -222 | Closed |
|
|
AA
79
Ancora Advisors
Cleveland,
Ohio
| – | -$266K | -63 | Closed |
|
|
RFC
80
Russell Frank Company
Seattle,
Washington
| – | -$223K | -53 | Closed |
|
81
ProShare Advisors
Bethesda,
Maryland
| – | -$157K | -38 | Closed |
|
82
JP Morgan Chase
New York
| – | -$128K | -30 | Closed |
|
|
BG
83
BlackRock Group
London,
United Kingdom
| – | -$85K | -20 | Closed |
|
|
FSA
84
Franklin Street Advisors
Chapel Hill,
North Carolina
| – | -$80K | -19 | Closed |
|
85
SG Americas Securities
New York
| – | -$78K | -19 | Closed |
|
86
Principal Financial Group
Des Moines,
Iowa
| – | -$64K | -15 | Closed |
|
87
Ameriprise
Minneapolis,
Minnesota
| – | -$9K | -2 | Closed |
|
|
FA
88
Financial Advantage
Columbia,
Maryland
| – | -$8K | -2 | Closed |
|
|
TRCT
89
Tower Research Capital (TRC)
New York
| – | -$5K | -1 | Closed |
|
|
PFG
90
Piershale Financial Group
Barrington,
Illinois
| – | -$1K | – | – |
|
GYRE Hedge Fund Activity: Q4 2013 in Review
74 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q4 2013, worth a combined $100M — down 25% from $135M a quarter earlier.
Fund positioning in GYRE was balanced in Q4 2013: 14 funds opened new positions, 14 closed out, 24 added to existing stakes and 20 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $3.09M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $11M sold.
- 74 institutional investors held Gyre Therapeutics (GYRE) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $100M of Gyre Therapeutics stock for Q4 2013, down 25% quarter-over-quarter.
- 14 funds opened new Gyre Therapeutics positions in Q4 2013 and 14 closed out, a net change of 0 holders.
- The largest Gyre Therapeutics buyer in Q4 2013 was Deerfield Management, an estimated $3.09M added.
- The largest Gyre Therapeutics seller in Q4 2013 was Baker Bros. Advisors, an estimated $11M sold.
Based on aggregated 13F filings for Q4 2013.